Get alerted on the PharmaSources E-Newsletter and Pharma Sources Insight E-Compilation!
Note: You can unsubscribe from the alerts at any time.
Advertising

GlaxoSmithKline to buy Tesaro for $5.1 billion, gaining PARP inhibitor Zejula

firstwordpharmaDecember 03, 2018

Tag: Zejula , PARP , Tesaro , GlaxoSmithKline , Inhibitor , Zejula

PharmaSources Customer Service